Advances in Tuberculosis Diagnosis, Pathophysiology, Treatment, and Therapy Duration (2020–2025): An Umbrella Review of Systematic Reviews and Meta-Analyses

Clicks: 1
ID: 314155
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #242 of 254 articles by views in Yemen Journal of Medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 254 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Tuberculosis (TB) remains a major global health threat despite advances in prevention and care, particularly among immunocompromised individuals and those with HIV coinfection. This umbrella review of systematic reviews and meta-analyses (January 2020–December 2025 synthesizes recent evidence on TB pathophysiology, diagnosis, treatment, and therapy duration, with emphasis on machine learning/artificial intelligence (ML/AI) applications and vulnerable populations. We searched PubMed, Scopus, Web of Science, and EMBASE for systematic reviews and meta-analyses using terms related to TB pathophysiology, diagnosis, treatment, therapy duration, and immunocompromised management, including ML/AI applications. Inclusion criteria: English-language publications, focus on human studies, and restriction from January 2020 to December 2025. As this is an umbrella review of existing systematic reviews and metaanalyses, findings were synthesized narratively. No new pooled analyses, meta-analyses, or meta-regressions were performed. Quantitative estimates are reproduced as reported in the source meta-analyses and attributed to those sources. Of 2000 identified records, 75 were included after screening and eligibility assessment (see PRISMA flow diagram). Significant findings encompass a deeper comprehension of immune dynamics in pathophysiology, increased diagnostic precision through AI and molecular methodologies, safer rifamycin-based therapies, and shorter treatment regimens demonstrating non-inferiority. AI and ML play a crucial role in enhancing predictive analytics and enabling personalization. In immunocompromised patients, HIV coinfection markedly deteriorates outcomes, while customized treatment regimens and AIbased predictions contribute to decreased mortality rates. Recent improvements in TB therapies enable the development of shorter and safer TB regimens, combined with integrated care for coinfections. Furthermore, including AI and ML has improved precision. However, challenges persist in resource-limited environments. Future research must emphasize implementation studies.
Reference Key
2026advances Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elmukhtar Habas, Amnna Rayani, Ala Habas, Mehdi Errayes
Journal Yemen Journal of Medicine
Year 2026
DOI
10.63475/yjm.v5i1.0323
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.